Abstract Purpose: Activity of ornithine decarboxylase (ODC), the first enzyme in polyamine synthesis, is required for normal growth and is elevated in many cancers, including colorectal cancer. We examined associations of the +316 ODC1 single nucleotide polymorphism (SNP) with colorectal cancer-specific survival among colorectal cancer cases, and then investigated its functional significance in colon cancer cells. Experimental Design: The study included 400 incident stage I-III colorectal cancer cases from the population-based University of California Irvine Gene-Environment Study of Familial Colorectal Cancer (diagnosed from 1994 to 1996 with follow-up through March 2008). The primary outcome was colorectal cancer-specific survival dependent on ODC1 (rs2302615) genotype (GG versus GA/AA). In human colon cancer cell lines, ODC1 allele-specific binding of E-box transcription factors was determined via Western blotting and chromatin immunoprecipitation assays. ODC1 allele-specific promoter activity was determined using promoter constructs in combination with vectors expressing either the transcriptional activator c-MYC or the repressor MAD1. Results: Genotype-specific survival differences were observed among colorectal cancer cases: compared with cases with the ODC1 GG genotype (hazards ratio, 1; reference) the adjusted colorectal cancer-specific survival hazards ratio was 2.02 (95% confidence interval, 1.17-3.50) for ODC1 GA/AA cases (P = 0.012). In colon cancer cells, the ODC1 SNP, flanked by two E-boxes, predicts ODC1 promoter activity. The E-box activator c-MYC and repressors MAD1 and MAD4 preferentially bind to ODC1 minor A-alleles, compared with major G-alleles, in cultured cells. Conclusions: These results have implications for conditional regulation of polyamine homeostasis and suggest a model in which the ODC1
adenomatous polyposis (4), a syndrome associated with high risk of colon and other cancers. Familial adenomatous polyposis is caused by mutations in the adenomatous polyposis coli (APC) tumor suppressor gene, and we have shown that wildtype APC signaling downregulates ODC1 expression in both human cells (5) and in a mouse model of familial adenomatous polyposis (6) . Wild-type APC expression leads to decreased expression of ODC, whereas mutant APC leads to increased expression of ODC. The mechanism of APC-dependent regulation of ODC involves E-box transcription factors, including the transcriptional activator c-MYC and the transcriptional repressor MAD1 (5, 7). c-MYC was shown by others to regulate ODC1 transcription (8) . Several genes involved in polyamine metabolism are essential genes for optimal growth in most organisms, and are downregulated in nonproliferating and/or adult cells and tissues (2) . The polyamines influence specific cellular phenotypes, in part, by affecting patterns of gene expression, as reviewed elsewhere (9) . D, L-α-diflouromethylornithine (DFMO), a selective ODC inhibitor, decreases APC-dependent intestinal tumorigenesis in mice (6) . Oral DFMO administered daily to humans inhibits ODC enzyme activity and polyamine contents in a number of epithelial tissues (10) (11) (12) (13) (14) (15) . Recently, DFMO in combination with the nonsteroidal anti-inflammatory drug sulindac has been reported to markedly lower the adenoma recurrence rate among individuals with colonic adenomas when compared with placebos in a randomized clinical trial (16) . We have associated a common single nucleotide polymorphism (SNP) in the ODC1 promoter, 316 nucleotides 3′ of the transcription start site, with decreased risk of colon polyp recurrence especially in people who report using aspirin (7) , and this latter finding has been confirmed by others (17, 18) . This SNP falls between two consensus E-box binding elements. Although the risk of adenoma recurrence based on ODC1 genotype has been investigated previously, the effects of this SNP on clinical outcomes after colorectal cancer diagnosis are unknown.
In this report, we studied the association of the ODC1 +316 SNP with colorectal cancer-specific mortality among colorectal cancer cases from a population-based study. Subsequently, using experimental models involving cultured colon cancer cells, we investigated the functional significance of the ODC1 SNP, as depicted in Fig. 1 . Previous work by our group and others has associated the ODC A-allele at +316 to reduced the risk of colon polyp recurrence (7) . Ornithine decarboxylase +316 genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention (18) . Visvanathan et al. (19) have reported results apparently at odds with our previous findings in colon carcinogenesis. Visvanathan and colleagues have associated the ODC1 A-allele at +316 with increased risk of prostate cancer. Our earlier functional studies using promoter reporter methods (7) showed that the repressor MAD1 could suppress the expression of the ODC1 promoter in an allele-specific manner. However, no direct evidence for binding of E-box transcription factors to the ODC1 promoter in an allele-specific manner has yet been reported. Consequently, we tested the hypothesis that both transcriptional activators and repressors might bind selectively to the ODC1 promoter in an allele-specific manner. Such allelespecific binding might explain the apparent discordant associations of this allele with both reduced risk of precancerous lesions but increased risk of invasive cancer, based on differences in the expression of E-box transcriptional activators and repressors. For example, c-MYC is known to be expressed at low levels in normal intestinal epithelium, but at high levels in intestinal polyps, in a mouse model of intestinal carcinogenesis (20) .
Materials and Methods
Epidemiologic studies: ODC1 +316 SNP associations with colorectal cancer-specific survival Study population. We studied incident cases of invasive colorectal cancer with stage I-III disease at presentation enrolled in the University of California, Irvine Gene-Environment Study of Familial Colorectal Cancer (21, 22) during the period 1994-1996 with follow-up through March 2008. The parent study was designed to determine the incidence of non-polyposis colon cancer in a large, population-based cohort of colorectal cancer cases. Participants were identified through the populationbased cancer registries of the Cancer Surveillance Program of Orange County/San Diego Imperial Organization for Cancer Control using the April 2008 data file. In the parent study (21) , all subjects with colorectal cancer diagnosed at all ages in Orange County, CA, from 1994 to1996 were ascertained. All subjects diagnosed in San Diego and Imperial Counties, CA, at ages <65 y in 1994 and 1995 were also ascertained. Cases were then contacted if they were eligible for the study Fig. 1 . Schema depicting the proposed differential effects of polyamine regulation by MAD1 and c-MYC on the ODC1 +316 minor A-allele. Effects of the ODC inhibitor DFMO (difluoromethylornithine) are also shown.
Translational Relevance
Excess polyamine formation has long been implicated in epithelial carcinogenesis, particularly colorectal carcinogenesis. Recently, a strategy involving inhibition of ornithine decarboxylase (ODC) activity (i.e., the rate-limiting enzyme of polyamine synthesis) has shown remarkable efficacy in preventing the recurrence of colorectal polyps in humans. Epidemiologic and experimental results from the present research show conditional regulation of polyamine homeostasis by genetic polymorphism in ODC1, and suggest a model in which the +316 ODC1 single nucleotide polymorphism may be protective for colon adenoma recurrence and detrimental for survival after diagnosis of nonmetastatic colorectal cancer. This information may be useful for determining colon cancer prognosis. By identifying patients at increased risk of cancer progression/ recurrence, early implementation of tertiary prevention management strategies could be instituted. Additionally, this research may help to identify high-risk but otherwise optimally treated locoregional colorectal cancer patients who would benefit from tertiary cancer prevention clinical trials.
(alive at the time ascertained and having a contact address) and if their physicians did not deny permission to contact. At the time of study entry, cases signed a consent form allowing for blood draws and the release of medical information. This study was approved by the University of California Irvine Institutional Review Board (#93-257). Clinical and demographic data including vital status and follow-up were obtained through linkage to the regional cancer registry databases as previously described (21) (22) (23) . Tumor grade was recorded according to standard convention: grade I, well-differentiated; grade II, moderately differentiated; grade III, poorly differentiated; grade IV, undifferentiated. Tumor, node, metastasis (TNM) staging determination was derived from existing American Joint Committee on Cancer (AJCC) codes where available and conversion of the extent of disease codes, as previously reported (24) . Family history of cancer in a first-degree relative was ascertained by self-reporting during a telephone interview conducted at enrollment (23, 25) . Twenty-two cases with hereditary non-polyposis colon cancer, as defined by Amsterdam criteria, were identified and excluded from the analysis. The median time from colorectal cancer diagnosis until study entry (i.e., date of family history interview) was 18 mo (95% confidence interval, 12-32 mo).
DNA extraction and ODC1 +316 SNP genotyping. DNA was extracted from 2 mL RBC clot samples using the QIAGEN QIAamp DNA Midi or Mini Kits (Qiagen), following the manufacturer's instructions. Genotyping of the ODC1 (National Center for Biotechnology Information SNP database ID rs2302615) +316 SNP was conducted using oligonucleotide primers designed to amplify a 172-bp fragment containing the polymorphic base at +316 (Applied Biosystems). Allele-specific TaqMan probes were synthesized with different 5′ labels (6-carboxyflourescein or VIC) and the same 3′ quencher dye (6-carboxytetramethylrhodamine; ref. 26) . Each PCR reaction (5 μL total) contained 10 ng of participant DNA, 30 pmol of each primer, 12.5 pmol of each TaqMan probe, and 1× TaqMan Universal PCR Master Mix (Applied Biosystems), as previously reported (7, 26) .
Statistical analysis -population-based study. An estimated 1:1 ratio of ODC1 GG genotype to ODC1 GA/AA genotype was expected based on previous literature (7, 17, 18, 26) . Of 481 DNA samples, 440 were Abbreviations: CRC, colorectal cancer; NOS, not otherwise specified.
successfully genotyped. A total of 41 cases (8.5%) resulted in an undetermined ODC1 +316 genotype due to low DNA concentration and/or poor DNA quality, but no clinicopathologic differences were observed between the successfully genotyped and unsuccessfully genotyped cases. The final analytic cohort was restricted to 400 colorectal cancer cases with stage I-III disease. Comparisons of demographic, clinical, and pathologic variables among colon and rectal cases were done using Pearson χ 2 statistic or Fisher's exact test for nominal variables and Student's t-test for continuous variables. Colorectal cancer-specific survival was defined as mortality from colorectal cancer itself, and data censoring occurred in the following instances: alive at the end of follow-up, loss to follow-up, or death from any cause other than colorectal cancer. Overall survival was defined as mortality from any cause. Survival curves were constructed for colon and rectal cancer cases using the Kaplan-Meier method and analyzed with the log rank test for univariate analyses. Cox proportional hazards modeling was done for all colorectal cancer cases, colon cancer cases, and rectal cancer cases using time since diagnosis to profile the adjusted risk of overall and colorectal cancer-specific death based on ODC1 genotype. The effects of ODC1 genotype on survival time were analyzed in the Cox models with stratification for TNM stage at diagnosis and adjustment for the following covariates: age, gender, ethnicity, family history of colorectal cancer, tumor site within the colon, histologic subtype, treatment with surgery, radiation therapy, and chemotherapy. For covariates with categorical data, dummy coding was assigned (0 or 1) and each category was included in the multivariate models in comparison with the referent group. ODC1 genotype was analyzed using the dominant model (GG versus GA/AA) with dummy variables, with GA/AA coded as 1 and GG as the referent group. Subset analyses were done using the additive model for ODC1 either as continuous variable 0, 1, and 2 test for trend, or using two dummy variables, one for GA and one for AA, with GG as the referent group. All analyses were conducted using SAS 9.2 statistical software (SAS Institute). Statistical significance was assumed for a two-tailed P < 0.05.
Experimental studies: ODC1 +316 SNP regulation in colon cancer cells Cell culture. The human colon cancer cell lines HT29 and HCT116 were maintained in McCoy's 5A medium (Invitrogen). All media used were supplemented with 10% fetal bovine serum plus 1% penicillin/ streptomycin solution (Invitrogen). Cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
Genotyping assay. DNA samples from HT29 and HCT116 cells were subjected to a PCR-restriction fragment length polymorphism procedure to detect the polymorphic PstI site. Sequences were amplified by PCR, using the following primers: 5′-TCTGCGCTTCCCCATGGGGCT-3′ and 5′-TTTCCCAACCCTTCG-3′. Each reaction contained 1 μL DNA, 4 pmol of each primer, 12.5 μL 2× PCR PreMixes buffer "G" (EPICENTRE Biotechnologies), and 0.5 unit of Taq DNA polymerase, in a final volume of 25 μL. The expected size of the PCR product was 351 bp. After amplification, 10 to 20 μL of the PCR product were digested with 10 units of PstI in 30 μL for 2 h at 37°C. DNA from HT29 cells (GA), containing the PstI site, yielded two fragments of 156 and 195 bp.
Western blot analysis. Cells were harvested, lysed, and proteins were separated on a 12.5% SDS-PAGE gel. Proteins were transferred by electrophoresis onto a Hybond-C membrane. The membrane was blocked with Blotto A (5% blocking grade dry milk in tris-tween buffered saline solution) and probed using 1:300 dilutions of primary antibodies (Santa Cruz Biotechnology) in Blotto A. Primary antibodies were incubated at 4°C overnight, followed by incubation with an appropriate horseradish peroxidase-tagged secondary antibody (1:1,000 dilution) for 1 h at room temperature. Chemiluminescent detection was conducted using ECL Western Detection reagent (Amersham Biosciences) and exposed on Biomax XAR film (Kodak).
Chromatin immunoprecipitation. Chromatin immunoprecipitation assays were done using a commercial kit, as recommended by the manufacturer (Upstate Biotech). Briefly, cells were treated with 1% formaldehyde to cross-link DNA and proteins, and DNA-protein complexes were disrupted by sonication to lengths between 200 and 1,000 bp. Lysates were diluted 10-fold with immunoprecipitation dilution buffer containing protease inhibitors. Antibodies for c-MYC, MAD1, and MAD4 (Santa Cruz Biotechnology) were used to precipitate chromatin, whereas an additional sample was left as a minus-antibody control. Samples were immunoprecipitated overnight at 4°C with rotation. Immune complexes were obtained by adding 60 μL of salmon sperm DNA/protein A Agarose slurry and incubating for 1 h at 4°C with rotation followed by gentle centrifugation (1,000 rpm, 1 min). Protein A agarose pellets were washed with low-salt buffer, high-salt buffer, LiCl buffer, and TE buffer. Then the complexes were eluted by adding 250 μL elution buffer (0.1 mol/L NaHCO 3 , 1% SDS) twice, and DNA-protein cross-links were reversed with 0.2 mol/L NaCl by heating at 65°C for 4 h for all samples, including the input DNA and minus-antibody DNA controls. DNA was resuspended in 30 μL of ddH 2 O. For visualization of PCR product and its size, standard PCR reactions were carried out. The sequences of ODC1 primers used for PCR were 5′-CCTGGGCGCTCTGAGGT-3′ (17mer) and 5′-AGGAAGCGGCGCCT-CAA-3′ (17mer). Quantitative real-time PCR was done using TaqMan gene expression assays kit (Applied Biosystems) on an ABI7700 sequence detection system. Details for the computation of relative binding can be found on the manufacturer's website (http://www. appliedbiosystems.com/).
Transient transfections. Transient transfections were done using LipofectAMINE reagent (Invitrogen) according to the manufacturer's protocol, as detailed in the supplementary file. HCT116 and HT29 cells were transfected with 1 μg of pGL3-ODC1/A or pGL3-ODC1/G plasmids (7) along with 0.01 μg of Renilla-TK plasmid. The Renilla-TK plasmid was purchased from Promega and used as a transfection efficiency control in all promoter-reporter transfection experiments. For MYC experiments, ODC1 pGL3-plasmids were cotransfected with either pcDNA 3.0 or CMV-MYC expression vector (OriGene). For MAD1 experiments, the ODC1 plasmids were cotransfected with either pcDNA 3.1 or pcDNA-MAD1. For MYC and MAD1 cotransfection, ODC1 promoter reporter constructs were prepared which contained the first 1.6 Kb of the ODC1 gene cloned into a pGL3 vector. The constructs included E-box 1 (-485 to -480 bp) intact (wt E-box 1) or deleted (mut E-box 1). Additionally, both variants of the +316 ODC1 SNP were used, creating a total of four different constructs. 
The next day after transfection 20% fetal bovine serum-containing complete medium was replaced with 10% fetal bovine serumcontaining medium. Forty-eight hours after transfection, cells were washed with PBS and lysed in Passive Lysis Buffer from the Dual Luciferase Assay kit (Promega). Dual luciferase activities were measured using a Turner Designs TD-20/20 luminometer, as described by the manufacturer, and presented as relative luciferase units. Experiments were done in triplicates and repeated at least twice.
Statistical
Results
Epidemiologic studies: association of the ODC1 +316 SNP with colorectal cancer-specific survival among colon and rectal cancer cases. A total of 400 stage I-III colorectal cancer cases identified from the University of California Irvine colorectal cancer gene-environment study were used in the case-only analysis. Median follow-up duration was 11 years, 1 month. There were 252 (63%) colon cancer cases, 143 (36%) rectal cancer cases, and 5 (1%) colorectal cancer cases of unspecified location. Clinicopathologic data for colorectal cancer cases are shown in Table 1 . Timing of radiation therapy was available for 60 cases (55 rectal and 5 colon cancer cases) of the 63 receiving radiation therapy. Thirteen (21.7%) received neoadjuvant (i.e., presurgery) radiation, 45 (75.0%) received adjuvant (i.e., postsurgery) radiation, and 2 (3.3%) received combination neoadjuvant and adjuvant radiation therapy. ODC1 genotype distribution among all colorectal cancer cases was 52% GG, 41% GA, and 7% AA. There were no significant differences in ODC1 genotype distribution (GG versus GA/AA) by age, gender, ethnicity, family history, stage, site within the colorectum, histology, or tumor grade (Table 1) . When analyzed by three genotypes (GG, GA, AA), ODC1 genotype distribution by ethnicity revealed significant differences: Caucasian (351 cases: 54% GG, 40% GA, 6% AA, minor-A allele frequency = 26%), African American (4 cases: 50% GG, 50% GA, 0% AA, minor-A allele frequency = 25%), Hispanics (20 cases: 55% GG, 45% GA, 0% AA, minor-A allele frequency = 23%), and Asians (23 cases: 30% GG, 44% GA, 26% AA, minor-A allele frequency = 48%; P = 0.012). However, within each race ODC1 genotype distribution was in Hardy-Weinberg equilibrium (Caucasians P = 0.51, African Americans P = 0.51, Hispanics P = 0.19, Asians P = 0.54).
Of the 400 stage I-III colorectal cancer cases, 109 (27%) were deceased at the time of analysis. Forty-seven (43%) deaths occurred in cases carrying the ODC1 GG genotype, compared with 62 (57%) deaths in cases with the GA/AA genotypes. Cause of death was available for 76 of the 109 deceased colorectal cancer cases. Fifty-nine (77%) colorectal cancer cases died as a result of colorectal cancer. A statistically significant improvement in colorectal cancer-specific survival was observed among colorectal cancer cases homozygous for the ODC1 G-allele (10-year survival, 89%) compared with cases with at least one A-allele (ODC1 GA/AA; 10-year survival, 81%; P = 0.011). Colorectal cancer-specific survival analysis by stage revealed that significantly different survival differences were not observed for AJCC stage I (P = 0.055) or II (P = 0.61) colorectal cancer. However, among cases with stage III colorectal cancer the ODC1 GG genotype was associated with improved 10-year colorectal cancerspecific survival at 75% compared with 60% for ODC1 GA/AA genotype cases (P = 0.024; Fig. 2 ). Among all cases (stage I-III), genotype-specific survival differences were significant for rectal (10-year overall survival, 88% for ODC1 GG versus 75% for ODC1 GA/AA; P = 0.041) but not colon cancer (10-year overall survival, 89% for ODC1 GG versus 84% for ODC1 GA/AA; P = 0.11). Among colorectal cancer cases, the colorectal cancer-specific survival estimates based on ODC1 genotype after stratification for TNM stage at diagnosis and adjustment for age (years), gender, ethnicity, family history of colorectal cancer, tumor site within the colon, histologic subtype, treatment with surgery, radiation therapy, and chemotherapy were a follows: ODC1 GG hazards ratio (HR), 1 (referent); ODC1 GA/AA HR, 2.02 (P = 0.021; Table 2 ). In the additive model, adjusted colorectal cancer-specific survival estimates were as follows: ODC1 GG HR, 1 (referent); ODC1 GA HR, 1.95; ODC1 AA HR, 2.25 (P-trend = 0.015). Subset multivariate colorectal cancer-specific survival analysis revealed that ODC1 genotype was a significant prognostic factor among rectal (ODC1 GA/ AA HR, 2.92; 95% confidence interval, 1.22-7.03 using ODC1 GG as a referent) but not colon cancer cases (ODC1 GA/AA HR, 1.76; 95% confidence interval, 0.85-3.63 using ODC1 GG as a referent). No significant associations with ODC1 genotype and overall survival were detected in subset-adjusted analyses of rectal, or colon cancer cases.
As noted above, the ODC1 +316 genotype distribution differed across ethnicity. The observed mortality risk, other than by chance, likely reflects differences based on ODC1 genotype, but the risk may be restricted to a particular ethnic group. Thus multivariate analyses were conducted among Caucasian colon cancer cases, to assess genotype-specific mortality risk within this single ethnic group. Among the 351 Caucasians, there were 52 colorectal cancer-related deaths. Multivariate colorectal cancer-specific survival analysis revealed that the ODC1 SNP was an independent predictor of colorectal cancer-specific survival among Caucasian colorectal cancer cases after adjustment for the aforementioned relevant clinical variables. Compared with cases with ODC1 GG genotype (HR, 1; reference), the colorectal cancer-specific risk of death (HR) was 2.37 (95% CI, 1.33-4.23) for ODC1 GA/AA genotype.
Experimental studies: ODC1 +316 SNP regulation in colon cancer cells ODC1 allele-specific binding of E-box transcription factors. We evaluated the functional significance of the +316 ODC1 SNP, located between two E-boxes (E-box 2 and 3 as depicted in Fig. 3A) . Each cell line genotype influences a consensus Pstl restriction site in this region. Figure 3B shows that a PCR product made from human colon HT29 cells was partially sensitive to PstI cutting, suggesting that these cells contained at least one ODC1 A-allele. A PCR product made from human colon HCT116 cells using the same primers was insensitive to PstI action, implying that these cells contained only ODC1 G-alleles. This result was confirmed by direct DNA sequencing (data not shown).
Expression of specific E-box binding proteins, including the transcriptional activator c-MYC and several transcriptional repressors in HT29 and HCT116 cells (e.g., MAD1 and MAD4), was established by Western blotting (Fig. 4A) . Chromatin immunoprecipitation analysis of the region surrounding +316 of the ODC1 promoter was conducted, using antibodies directed against these proteins. As shown in Fig. 4B , ODC1 promoterspecific PCR products were synthesized from HT29 DNA obtained after immunoprecipitation of chromatin with antibodies directed against c-MYC, MAD1, or MAD4. PCR products Fig. 3 . A, location of the ODC1 promoter SNP. The SNP under investigation in this study is 316 nucleotides 3′ of the ODC1 transcription start site (*). This SNP resides between two consensus E-boxes as shown by the underlined sequences, and affects a PstI restriction site (box). B, restriction fragment length polymorphism analysis of ODC1 SNP. DNA was obtained from two cell types, and the region surrounding the ODC1 SNP site was sequenced. Colon-derived HT29 cells were found to be heterozygous GA, whereas HCT116 cells were found to be homozygous GG, at the ODC1 SNP locus. A 350-bp PCR product of this region was obtained from each cell type and subjected to digestion with PstI. Evidence of an A-allele was indicated by restriction products <350 bp. Fig. 4 . A, E-box protein expression in colon-derived cells. Expression of proteins to be evaluated for binding to the +316 ODC1 SNP was assessed by Western blot analysis. Extracts of both HT29 and HCT116 cells were evaluated for c-MYC, MAD1, and MAD4; β-actin was used as a loading control. B, documentation of allele-specific transcription factor binding by chromatin immunoprecipitation analysis, which was conducted as described in Materials and Methods. HT29 cells were a source of ODC1 A-alleles, as these cells are heterozygous GA at this site. HCT116 cells were used as a source of ODC1 G-alleles.
synthesized from HCT116 DNA after similar chromatin immunoprecipitation were substantially reduced compared with those synthesized from HT29 DNA. Quantification of these results indicated that c-MYC, MAD1, and MAD4 binding to the ODC1 SNP region were 4 to 14 times greater in HT29 cells, which contained one ODC1-A allele, compared with HCT116 cells, which contained only ODC1-G alleles (Supplementary Table) .
ODC1 allele-specific promoter activity. We tested the hypothesis that +316 ODC1 SNP influenced ODC1 expression in a manner dependant on the expression of E-box activators and repressors. Transient cotransfection of colon cancer-derived HT29 cells was accomplished with ODC1 allele-specific promoter constructs in combination with vectors expressing either the transcriptional activator MYC or the repressor MAD1 (Fig. 5) . The SE bars shown reflect the variability in triplicate measurements within a single representative experiment, which has been replicated. The allele-specific promoter-reporters used in these experiments included all three E-boxes shown in Fig. 3A . As shown in Fig. 5A , MYC expression had the greatest stimulatory effect on promoters containing three consensus Eboxes and the ODC1-A allele (wt E-box1 +316 A, P = 0.0014). Deletion of the upstream E-box reduced promoter activity, but MYC expression continued to stimulate this activity (mut Ebox1 +316 A, P = 0.0013). Substitution of a G for the A at the ODC1 +316 SNP position reduced the ability of c-MYC to stimulate promoter activity even with an intact 5′ flanking consensus E-box. Mutation of the 5′ flanking consensus E-box in combination with the ODC1-G allele further reduced promoter activity.
When MAD1, rather than MYC, was cotransfected with the ODC1 allele-specific promoter reporters (Fig. 5B ), the repressor was only able to reduce the activity of the ODC1 promoter which contained all three E-boxes and the wild-type +316 Aallele (P = 0.027). Deletion of the upstream E-box (mut E-box 1 +316A) significantly reduced the effect of MAD1 on ODC1 promoter activity. Substitution of G for A at the +316 position rendered promoters containing either two or three E-boxes unresponsive to MAD1 suppression.
Discussion
In our population-based analysis of colorectal cancer cases with >11 years follow-up duration, we observed that the +316 ODC1 SNP was associated with colorectal cancer-specific survival among colorectal cancer cases, with a greater association observed among rectal cancer cases. A statistically significant increased risk of colorectal cancer-specific mortality was observed for ODC1 GA/AA cases among rectal cancer cases, after stratification for stage and adjustment for age, gender, ethnicity, family history of colorectal cancer, tumor site, histology, treatment with surgery, radiation therapy, and chemotherapy.
The experimental data presented here provide insights into potential biological mechanisms underlying our clinical observations. In colon cancer epithelial cells, we have shown that the ODC1 +316 SNP is functionally significant, as evidenced by increased binding of E-box transcription factors to promoter elements containing A-alleles, compared with G-alleles. Both the activator c-MYC and the repressor MAD1 show greater effects on promoter activity in reporter elements containing A-versus G-alleles. These results suggest allele-specific regulation of ODC1 by E-box transcription factors. ODC protein enzyme activity is not apparently affected by the ODC1 +316 SNP genotype, which we believe influences ODC1 transcription.
In colon cells, we have shown that conditional expression of wild-type APC, a gene expressed in normal colonic mucosa, suppresses MYC, and increases MAD1, expression (5) . Further, we have reported that wild-type APC can regulate ODC1 promoter activity in a manner dependent on the +316 SNP (7). Wild-type APC is expressed in the apparently normal colonic mucosa of individuals not afflicted with familial adenomatous polyposis, whereas the majority of sporadic colon adenomas show evidence of mutated or deleted APC (27) . MYC is expressed at low levels in normal intestinal mucosa but is increased in intestinal adenomas of APC Min/+ mice. Conditional knockout of intestinal epithelial MYC expression suppresses intestinal tumorigenesis in APC Min/+ mice (20). As described above, previous work by our group (7) and others (18) showed Promoter constructs differ by the presence of the first E-box element, located in -485 to -480 bp ("wt E-box1" for the wild-type sequence or "mut E-box1" for a mutant sequence). The constructs differ also by the ODC1 +316 SNP ("+316 G" or "+316 A"). *, P ≤ 0.013 for each of the four comparisons relative to promoter activity with pcDNA 3.0 cotransfection. B, effect of MAD1 expression on ODC1 allele-specific promoter activity in HT29 colon tumor derived cells. Promoter activity was measured after transfection with ODC1 promoter reporter plasmids cotransfected with pcDNA 3.1 plasmid (□) or with a pcDNA-MAD1 plasmid ( ▪ ). Promoter constructs used were described in the legend for panel A of this figure. *, P = 0.027, statistical significance relative to promoter activity with pcDNA 3.1 cotransfection.
a protective role for the ODC1 A-allele, especially in aspirin users, against recurrence of colon polyps in clinical prevention trials. However, in the population-based study presented here, the ODC1 A-allele was associated with poor survival. This apparent contradiction may be explained by the results shown here, which indicate that both E-box activators and repressors bind the ODC1 A-allele selectively. If the transformed epithelium begins to express E-box activators (such as c-MYC), then cancer progression may be more likely to occur in individuals with the ODC1 A-allele genotype. Our results for risk of colon cancer-specific mortality are consistent with those of others showing that risk of prostate cancer may be associated with the ODC1 A-allele among specific individuals as the result of gene environment interactions (19, 28) . Such colon cancer progression could be due to enhanced polyamine synthesis, as has been shown already for prostate cancer (15) .
Our finding that a factor, such as the ODC1 SNP, may have both promoting and inhibiting effects on carcinogenesis is not unique. For example, transforming growth factor-β has diverse roles in carcinogenesis and cancer progression (29) (30) (31) . Transforming growth factor-β in untransformed cells inhibits cell proliferation and induces apoptosis. Yet, it is overexpressed in all human tumors and is associated with late cancer progression, specifically tumor invasion and metastasis. A single study by Matsubara et al. reporting ODC1 activity in human colorectal tumors showed that high levels of ODC1 expression were significantly associated with improved survival (32) . This suggests that, although ODC1 overexpression promotes the formation of human colorectal adenomas, it is possible that in established lesions, ODC1 overexpression causes enhanced proliferation and is associated with improved response to antiproliferative treatments. However, that study did not include stratification by ODC1 genotype, so it is not known if these effects are independent of ODC1 genotype. Population differences between the Matsubara et al. study and ours could account for the differences. For example, the former study included few rectal cancers (5%), whereas our study cohort comprised a substantial proportion of rectal cancer cases (36%). This difference is not trivial, because the observed associations of the ODC1 SNP with colorectal cancer-specific survival were greater for rectal compared with colon cancer cases. The Matsubara et al. study comprised 63.5% females compared with our study which included 41% females. Furthermore, the distribution by race/ethnicity differs substantially between the two studies. Additionally, chance variation could explain why our findings differ from the prior analysis.
The observed associations of the ODC1 +316 SNP with colorectal cancer-specific mortality were greatest among rectal cancer cases. Among all colorectal cancer cases, particularly strong effects were observed for Caucasians. Similar to other reports, the ODC1 +316 SNP allele frequency differs considerably by ethnicity (28) . When we limited the survival analysis to Caucasians only (i.e., the only ethnic group with adequate power to test for such analyses), the associations of the ODC1 +316 SNP were significant and of greater magnitude than the estimates observed for the entire cohort.
The epidemiologic study shares limitations of other population-based analyses, including lack of data on comorbid conditions, performance status, and particular chemotherapeutic regimens utilized. Additionally, the tissue biopsy samples obtained from participants of the University of California Irvine Gene-Environment Study of Familial Colorectal Cancer were paraffin-embedded specimens and therefore could not be used for accurate assessment of tissue polyamine quantification by highperformance liquid chromatography. There is also the potential for selection bias, favoring a relatively healthy group of colorectal cancer survivors, because there was a median 18-month delay from the time of colorectal cancer diagnosis until study enrollment. Other factors affecting polyamine metabolism that were not accounted for in the present study may explain our observations. For example, aspirin activates polyamine acetylation and export, and works with the ODC1 A-allele to reduce cell and tissue polyamine contents (2, 7, 33) . Our experimental findings are limited to the effects of the ODC1 +316 SNP in two colon cancer cell lines. Thus, validation of our findings is warranted.
In summary, we have observed clinical consequences of the ODC1 +316 SNP on colorectal cancer-specific mortality among colorectal cancer cases. Additionally, we have further established the functional significance of the ODC1 +316 SNP in the c-MYC-and MAD1-dependent transcription of this gene in human colon cancer cells. Together, these experimental and epidemiologic findings suggest a role for the ODC1 SNP in progression of colorectal cancer distinct from its previously reported role in progression to colon adenomas. Provided that our results are validated in future research, these novel findings may contribute to our ability to assess risk of colorectal cancer progression and may direct patient-specific pharmacogenetic management, surveillance monitoring, and inform novel targeted approaches to secondary and tertiary colorectal cancer prevention.
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